Compare ELTK & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTK | XBIT |
|---|---|---|
| Founded | 1970 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.0M | 74.4M |
| IPO Year | 1998 | 2015 |
| Metric | ELTK | XBIT |
|---|---|---|
| Price | $9.45 | $2.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.7K | ★ 26.3K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.71 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.30 | $2.09 |
| 52 Week High | $12.19 | $3.61 |
| Indicator | ELTK | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 56.45 | 36.14 |
| Support Level | $8.05 | $2.26 |
| Resistance Level | $11.52 | $2.67 |
| Average True Range (ATR) | 0.66 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 32.62 | 0.00 |
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. The company manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. The geographic areas of the company are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.